PPARG and metabolic dysfunction-associated steatohepatitis: For example, PPAR-γ agonists, such as Pioglitazone and Elafibranor, are currently undergoing Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH)-related liver fibrosis (Burns et al., 2021; Harrison et al., 2023; Schattenberg et al., 2021).